GlassScriptPhysician profile
Irma Valdez
NPI 1952840027
$4,449.02
in general payments reported to CMS, 2019-2025
14 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $985 · 2023: $209 · 2024: $946 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,907 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,907.38 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,190.15 | 2021-2023 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $581.87 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $438.91 | 2024-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $404.22 | 2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $354.01 | 2024-2025 | Invega Sustenna, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $272.02 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $227.57 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.11 | 2024-2025 | Caplyta |
| Medtronic, INC. | $157.59 | 2024 | Signia |
| Vanda Pharmaceuticals INC. | $124.99 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $124.92 | 2025 | Auvelity |
| Lilly USA, LLC | $124.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.06 | 2025 | Cobenfy |
| Eisai INC. | $118.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irma Valdez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.